Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Critical Limb Ischemia
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Leg Pain
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Enrollment
- 15
- Locations
- 2
- Primary Endpoint
- Major amputation
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to determine if stem cell therapy with one's own cells (autologous cells) delivered intramuscularly to one's leg with ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.
Detailed Description
Chronic critical limb ischemia (CLI) is a progressive disease, which arises as a result of atherosclerosis or vasculitis in leg arteries. Prognosis of chronic CLI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the leg arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with chronic CLI who are not eligible for traditional revascularization treatments. The primary endpoint is the primary efficacy score identified by toe brachial blood pressure index (TBPI), absolute claudication distance (ACD) and Wong Baker's pain rating scale, while the secondary endpoints are evaluation of safety, ankle brachial blood pressure index (ABPI), percutaneous tissue oxygen pressure (TcPO2), etc.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Chronic severe CLI patients fulfilling all the following criteria are considered suitable for inclusion in the study.
- •At least 6 months since the onset of CLI (Chronic peripheral artery disease or Buerger disease)
- •Patients with luminal stenosis \> 50% by leg angiography
- •Age is between 20 and
- •Patients whose Rutherford's class is II-4, III-5, or III-6（Patients with rest pain or ischemic ulcer/necrosis)
- •Patients for whom angioplasty and bypass surgery are not indicated because of anatomical or procedural reasons or frequent reocclusion/ restenosis following the traditional revascularization (No option patients)
- •Patients who can give informed consent themselves in writing.
Exclusion Criteria
- •Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.
- •Left ventricular ejection fraction \< 25%
- •Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.
- •Less than 6 months since last episode of myocardial/cerebral infarction.
- •Patients with unstable angina, with a treatment rating of 3 in the Braunwald system, but a severity of III and a clinical rating of B or C.
- •Patients with diabetic proliferating retinopathy (new Fukuda classification BI to BV).
- •Patients with malignant tumor
- •Patients with chronic rheumatoid arthritis.
- •Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
- •Patients currently suffering from or having a history of interstitial pneumonitis.
Outcomes
Primary Outcomes
Major amputation
Secondary Outcomes
- Limb ischemia